Upgrade to SI Premium - Free Trial

Merck to Collaborate with Generex to Evaluate KEYTRUDA (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer

July 31, 2017 9:41 AM
Merck (NYSE: MRK) (known as MSD outside the United States and Canada), through a wholly-owned subsidiary today announced that through ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Management Comments

Next Articles